Female Contraception - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 86
Inquire Before Buying

Female Contraception - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H1 2018, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 5, 3, 8 and 4 respectively. Similarly, the Universities portfolio in Pre-Registration, Phase II and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).

- The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Female Contraception - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Contraception - Overview
Female Contraception - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Female Contraception - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Contraception - Companies Involved in Therapeutics Development
Agile Therapeutics Inc
Bayer AG
Evofem Biosciences Inc
Hervana Ltd
MedinCell SA
Mithra Pharmaceuticals SA
Orbis Biosciences Inc
Teva Pharmaceutical Industries Ltd
Viramal Ltd
Female Contraception - Drug Profiles
(anastrozole + levonorgestrel) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(dienogest + ethinyl estradiol) PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(drospirenone + estetrol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(estradiol + segesterone acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ethinylestradiol + segesterone acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-200 ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-200 SP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-20015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Amphora - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
drospirenone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etonogestrel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etonogestrel ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDC-WWM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-003296 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TV-46046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Contraception - Dormant Projects
Female Contraception - Discontinued Products
Female Contraception - Product Development Milestones
Featured News & Press Releases
May 03, 2018: Mithra Announces Last Subject Visit in Estelle Phase III Study in EU/Russia and Completion of Endometrial Substudy
Mar 28, 2018: Mithra Applies For Additional Estelle Patent Based On Positive Hemostasis Data
Mar 23, 2018: Mithra Announces Completion of Estelle Cycles Required In Phase Iii Contraception Studies
Jan 23, 2018: Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019
Jan 03, 2018: Population Councils One-Year Contraceptive Ring Advances to FDA Review
Dec 07, 2017: MedinCell receives grant to develop long-acting injectable contraceptive
Nov 30, 2017: Mithra Provides Update On Estelle Study
Oct 30, 2017: Mithra Completes Recruitment for Estelle Phase III Study in US & Canada
Oct 30, 2017: Mithra Completes Recruitment for Estelle Phase III Study in US and Canada
Aug 18, 2017: Mithra Announces First Subject Completes Estelle Phase III Study
Aug 09, 2017: Mithra Pharmaceuticals: Recruitment Completed in Estelle Population PK Sub study
Jul 27, 2017: Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA for Prevention of Pregnancy
Jun 26, 2017: Estelle Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal
May 12, 2017: Mithra to Initiate PK Study for Estelle
Feb 07, 2017: Mithra Completes Recruitment For European Phase III Estelle Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Female Contraception, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Female Contraception - Pipeline by Agile Therapeutics Inc, H1 2018
Female Contraception - Pipeline by Bayer AG, H1 2018
Female Contraception - Pipeline by Evofem Biosciences Inc, H1 2018
Female Contraception - Pipeline by Hervana Ltd, H1 2018
Female Contraception - Pipeline by MedinCell SA, H1 2018
Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H1 2018
Female Contraception - Pipeline by Orbis Biosciences Inc, H1 2018
Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
Female Contraception - Pipeline by Viramal Ltd, H1 2018
Female Contraception - Dormant Projects, H1 2018
Female Contraception - Dormant Projects, H1 2018 (Contd..1), H1 2018
Female Contraception - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Female Contraception, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Anti-infective Ophthalmic Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 122
    Ophthalmic anti-infectives are anti-infectives contained in a product formulated especially to be instilled or applied in the eye or eyes. Ophthalmic anti-infectives include eyedrops, gels or ointments. Anti-infectives are drugs that can either kill an infectious agent or inhibit it from spreading. Anti-infectives include antibiotics and antibacterials, antifungals, antivirals and antiprotozoals. Scope of the Report: This report focuses on the Anti-infective Ophthal......
  • Global Cannabis Oil Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 124
    Cannabis oil is from the marijuana plant (cannabis indicas). The oil is extracted from the leaves of the cannabis plant. It contains high levels of THC. It is used for medicinal purposes and as a recreational drug. Cannabis oil reached considerable popularity when a man in Canada named Rick Simpson began distributing this concentrate, albeit illegally, as a medicine. Rick's oil (commonly known as "Rick Simpson oil") brought the long studied knowledge about the anti-tumor and various medi......
  • Global Darbepoetin Alfa Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 124
    Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic renal failure and ......
  • Global Hemostasis and Tissue Sealing Agents Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 136
    Hemostasis is a process which causes bleeding to stop, meaning to keep blood within a damaged blood vessel (the opposite of hemostasis is hemorrhage). It is the first stage of wound healing. Tissue sealing agents are used during medical procedures to achieve hemostasis. They vary based on their mechanism of action, composition, ease of application, adherence to tissue, immunogenicity and cost. These agents permit rapid hemostasis, better Visualization of the surgical area, shorter operati......
  • Global Humira Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 121
    Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation. Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa. Humira is also used in adults and children to treat Crohn's disease or juvenile idiopathic arthritis. ......
  • Global Hypromellose Acetate Succinate Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 119
    Hypromellose acetate succinate is an enteric coating material which was first approved in Japan in 1987. As of January 2004, this product has been approved in Korea, several countries in Europe, and USA as well as in Japan. Scope of the Report: This report focuses on the Hypromellose Acetate Succinate in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manuf......
  • Global IGY Polyclonal Antibodies Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 120
    Immunoglobulin Y (abbreviated as IgY) is a type of immunoglobulin which is the major antibody in bird, reptile, and lungfish blood. It is also found in high concentrations in chicken egg yolk. As with the other immunoglobulins, IgY is a class of proteins which are formed by the immune system in reaction to certain foreign substances, and specifically recognize them. IgY antibodies have a different structure from IgG, particularly in the Fc and hinge regions. The affinity maturation proces......
  • Global Platinum based Cancer Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 122
    Platinum-based antineoplastic drugs (informally called platins) are chemotherapeutic agents used to treat cancer. They are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, popular drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development. Scope of the Report: This report focuses on the Platinum based Cancer Drug......
  • Global Hepatocyte Growth Factor Market Professional Survey Report 2018
    Published: 20-Aug-2018        Price: US 3500 Onwards        Pages: 104
    This report studies the global Hepatocyte Growth Factor market status and forecast, categorizes the global Hepatocyte Growth Factor market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility a......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs